Skip to main content

Advertisement

Table 2 Clinical characteristics of Parkinson’s disease patients with mild to moderate and severe non-motor symptoms burden

From: Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson’s disease

  PD mild to moderate NMS burden (NMSS = 0–40) PD severe NMS burden (NMSS ≥ 41)
No (%) 23 (56.1%) 18 (43.9%)
Gender (M, %) 15 (65.2%) 9 (50%)
Age (years; median ± SD) 58.5 ± 8.9 70.3 ± 8.3*
Disease durationa (months; median ± SD) 16.1 ± 60.4 108.0 ± 73.8*
Daily LED (mg; median ± SD) 250.3 ± 438.3 690.0 ± 1219.6*
H&Y OFF (median ± SD) 1.0 ± 0.8 2.3 ± 1.2*
MMSE (median ± SD) 30.0 ± 1.6 29.5 ± 1.3
PDQ-39 (median ± SD) 9.5 ± 16.1 47.0 ± 24.4***
  1. H&Y Hoehn & Yahr, LED levodopa equivalent dose, MMSE mini mental status examination, NMSS Non-motor Symptoms Scale, PDQ-39 39-item Parkinson’s disease Questionnaire, UPDRS-III Unified Parkinson’s Disease Rating Scale part III
  2. *P < 0.05; ***P < 0.001
  3. aFrom time of first appearance of Parkinson’s disease motor symptoms